Cisatracurium in intensive care

Current Opinion in Anaesthesiology

Volumn 9, Issue SUPPL. 1, 1996, Pages

  Bion, Julian ^a   Prielipp, Richard C ^b   Bihari, David ^c   Grounds, Michael ^d   Harper, Nigel ^e   Hunter, Jennifer M ^f   Pollard, Brian ^e   Pearson, Jane ^e   Coursin, Douglas B ^g   Murray, Michael J ^h   Prough, Donald S ⁱ   Scuderi, Phillip ^b   Vender, Jeffrey S ^j  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g University of Wisconsin Health   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; NEUROMUSCULAR BLOCKING AGENT; VECURONIUM;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTENSIVE CARE; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MUSCLE TWITCH; MUSCLE WEAKNESS; MYOPATHY; NEUROMUSCULAR BLOCKING; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 9344234977     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199604001-00010     Document Type: Conference Paper

References (63)

1. Hansen-Flaschen JH, Brazinsky S, Basile C, Unken PN: Use of sedation drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey. JAMA 1991, 226: 2870-2875.
2. Hickling KG: Low volume ventilation with permissive hypercapnia in the adult respiratory distress syndrome. Clin Intensive Care 1992, 3:67-68.
3. Wingard LB, Cook DR: Clinical pharmacokinetics of muscle relaxants. Clin Pharmacokinet 1977, 2:330-343.
4. Fry DE: Multiple system organ failure. Surg Clin North Am 1983, 68:107-122.
5. Heard SO, Fink MP: Multiple organ failure syndrome. Part I: Epidemiology, prognosis and pathophysiology. J Intensive Care Med 1991, 6:279-294.
6. Hughes R, Chapple DJ: Effects of non-depolarising neuromuscular agents on peripheral autonomic mechanisms in the cat. Br J Anaesth 1976, 48: 59-68.
7. Vandenbrom RHG, Wierda MKH: Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology 1988, 69:996-997.
8. Segredo V, Matthay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD: Prolonged neuromuscular block after long-term administration of vecuronium in two critically III patients. Anesthesiology 1990, 72:566-570.
9. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD: Persistent paralysis In critically III patients after long-term administration of vecuronium. N Engl J Med 1992, 327:524-528.
10. Clyburn PA, Marshall RD: Control of ventilation by continuous infusion of pancuronium bromide. Anaesthesia 1981, 36:860-862.
11. Shanks AB, Long T, Aitkenhead AR: Prolonged neuromuscular blockade following vecuronium. Br J Anaesth 1985, 57:807-810.
12. Cody MW, Dormon FM: Recurarization after vecuronium in a patient with renal failure. Anaesthesia 1987, 42:993-995.
13. Smith CL, Hunter JM, Jones RS: Vecuronium infusions in patients with renal failure in an ITU. Anaesthesia 1987, 42:387-393.
14. Slater RM, Pollard BJ, Doran BRH: Prolonged neuromuscular blockade with vecuronium in renal failure. Anaesthesia 1988, 43:250-251.
15. Kupfer Y, Namba T, Kaldawi E, Tessler S: Prolonged weakness after long-term infusion of vecuronium bromide. Ann Intern Med 1992, 117:484-486.
16. Partridge BL, Abrahams JH, Bazemore C, Rubin R: Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990, 18:1177-1179.
17. Rossiter A, Souney PF, McGowan S, Carvajal P: Pancuronium-induced prolonged neuromuscular blockade. Crit Care Med 1991, 19:1583-1587.
18. Murray MJ, Strickland RA, Weiler C: The use of neuromuscular blocking drugs in the intensive care unit: a US perspective. Intensive Care Med 1993, 19 (suppl 2):S40-S44.
19. Op de Coul AAW, Lambregts PCLA, Loeman J, Van Pyenbroek MJE, Ter Laak HJ, Gabreels-Festen AAWM: Neuromuscular complications in patients given Pavalon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosci 1985, 87:17-22.
20. Benzing G, Iannoccone ST, Bove KE, Keebler PJ, Shockley LL: Prolonged myasthenic syndrome after one week of muscle relaxants. Pediatric Neurol 1990, 6:190-196.
21. Rascucci RC: Prolonged weakness after extended mechanical ventilation In a child. Crit Care Med 1990, 18:1177-1179.
22. Griffin D, Fairman N, Coursin D, Rawsthorne L, Grossman JE: Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992, 102:510-514.
23. Subramony SH, Carpenter DE, Raju S, Pride M, Evans OB: Myopathy and prolonged neuromuscular blockade after lung transplant. Crit Care Med 1991, 19:1580-1582.
24. Danon MJ, Carpenter S: Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve 1991, 14:1131-1139.
25. Vanderheyden BA, Reynolds HN, Gerald KB, Emanuelle T: Prolonged paralysis after long-term vecuronium infusion. Crit Care Med 1992, 20:304-307.
26. Margolis BD, Khachikan D, Friedman Y, Garrard C: Prolonged reversible quadriparesis in mechanically ventilated patients who received long-term infusions of vecuronium. Chest 1991, 100:877-878.
27. Gooch JL, Suchyta MR, Balbierz JM, Petajan JH, Clemmer TP: Prolonged paralysis after treatment with neuromuscular junction blocking agents. Crit Care Med 1991, 19:1125-1131.
28. Meyer KC, Prielipp RC, Grossman JE, Coursin DB: Prolonged weakness after infusion of atracurlum in two intensive care unit patients. Anesth Analg 1994, 78:772-774.
29. Raps EC, Bird SJ, Hansen-Flaschens J: Prolonged muscle weakness after neuromuscular blockade in the intensive care unit. Crit Care Clin 1994, 10:799-813.
30. Coakley JH, Nagendran K, Honavar M, Hinds CJ: Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Care Med 1993, 19:323-328.
31. Bolton CF, Young GB, Zochodne DW: The neurological complications of sepsis. Ann Neurol 1993, 33:94-100.
32. Beemer GH, Bjorksten AR: Pharmacodynamics of atracurium in clinical practice: effect of plasma potassium, patient demographics, and concurrent medication. Anesth Analg 1993, 76:1288-1295.
33. Feldman SA: Effects of changes in electrolytes, hydration and pH upon the reactions to muscle relaxants. Br J Anaesth 1963, 35:546-551.
34. Waud BE, Waud DR: Interaction of calcium and potassium with neuromuscular blocking agents. Br J Anaesth 1980, 52:863-866.
35. Buzello W, Schluermann D, Schindler M, Spillner G: Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology 1985, 62:201-204.
36. Bevan DR, Bevan JC, Donati F: Muscle Relaxants in Clinical Anesthesia. Chicago: Year Book Medical Publishers; 1988.
37. Klessig HT, Geiger HJ, Murray MJ, Coursin DB: A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med 1992, 20:1341-1345.
38. Bencini AF, Scaf AHJ, Sohn YJ, Kersten-Kleef UW, Agoston S: Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 1986, 58:988-995.
39. Marshall IG, Gibb AJ, Durrant NN: Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat. Br J Anaesth 1983, 55:703-714.
40. Agoston S, Vermoor GA, Kersten UW, Meijer DKF: The fate of pancuronium bromide in man. Acta Anaesthesiol Scand 1973, 17:267-275.
41. Miller RD, Eger EI, Stevens WC, Gibbons R: Pancuronium-induced tachycardia in relation to alveolar halothane, dose of pancuronium and prior atropine. Anesthesiology 1975, 42:352-355.
42. Pollard BJ: Which drug: steroid or benzylisoquinolinium? Intensive Care Med 1993, 19 (suppl 2):S86-S90.
43. Stenlake JB, Waigh RD, Dewar GH, Hughes R, Chapple DJ, Coker GG: Biodegradeable neuromuscular blocking agents: Part 4. Atracurium besylate and related polyalkylene diesters. Eur J Med Chem 1981, 16:515-524.
44. Griffiths RB, Hunter JM, Jones RS: Atracurium infusions in patients with renal failure on an ITU. Anaesthesia 1986, 41:375-381.
45. Chapple DJ, Miller AA, Ward JB, Wheatley PL: Cardiovascular and neurological effects of laudanosine. Br J Anaesth 1987, 59:218-225.
46. Basta SJ, Savarese JJ, Ali HH, Moss J, Gioufriddo M: Histamine releasing potencies of atracurium, dimethylcurarine, and tubocurarine. Br J Anaesth 1983, 55:1055-1065.
47. Yate PM, Flynn PJ, Arnold RW, Weatherly BC, Simmonds RJ, Dopson T: Clinical experience and plasma isudanosine concentrations during the infusion of atracurium in the intensive therapy unit. Br J Anaesth 1987, 59: 211-217.
48. Parker CJR, Jones JE, Hunter JM: Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Br J Anaesth 1988, 61:531-540.
49. Welch R, Brown A, Dahl R: In vivo degradation of cisatracurium in Sørensen buffer, rat, and human plasma. Clin Pharmacol Ther 1995, 58:132-142.
50. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ, Vender J, Howard D, Casale EJ, Murray MJ: Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analges 1995, 81:3-12.
51. Boyd AH, Eastwood NB, Parker CJR, Hunter JM: A comparison of the pharmacodynamics and pharmacokinetics of an infusion of cisatracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in the intensive therapy unit. Br J Anaesth 1996, in press.
52. Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BD: Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Med 1993, 19 (suppl 2):S94-S98.
53. Savarese JJ, Deriaz H, Mellinghoff H, Pavlin E, Sokoll MD: The pharmacodynamics of cisatracurium in healthy adults. Curr Opin Anaesthesiol 1995, 8 (suppl 1):S16-S22.
54. Smith CE, Van Miers MM, Parker CJR, Hunter JM: The pharmacokinetics of 51W89 administered by constant infusion: a comparison with atracurium besylate [abstract]. Br J Anaesth 1995, 75:651P.
55. Stone AJ, Pollard BJ, Harper NJN: Infusion requirements of patients receiving 51W89 in the intensive care unit [abstract]. Br J Anaesth 1994, 72:486P.
56. Agoston S, Salt P, Newton A, Bencini A, Boomsma P, Erdmann W: The neuromuscular blocking action of Org NC45 a new pancuronium derivative in anaesthetized patients. Br J Anaesthes 1980, 52 (suppl 1):53S-59S.
57. Shi WZ, Fahey MR, Fisher DM, Miller RD: Modification of central nervous system effects of laudanosine by inhalation anaesthetics. Br J Anaesth 1989, 63:598-600.
58. Hennis PJ, Fahey MR, Miller RD, Canfell C, Shi WZ: Pharmacology of laudanoslne in dogs [abstract]. Anesthesiology 1984, 61:A305.
59. Ingram MD, Sclabassi RJ, Cook DR, Stiller RL, Bennett MH: Cardiovascular and electroencephalographic effects of laudanosine in 'nephrectomised' cats. Br J Anaesth 1986, 58 (suppl 1):14S-18S.
60. Peat SJ, Potter DR, Hunter JM: The prolonged use of atracurium in a patient with tetanus. Anaesthesia 1988, 43:962-963.
61. Pollard BJ, Harper NJN, Doran BRH: Use of continuous prolonged administration of atracurium in the ITU to a patient with myasthenia gravis. Br J Anaesth 1989, 62:95-97.
62. Gwinnutt CL, Eddelston JM, Edwards D, Pollard BJ: Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. Br J Anaesth 1990, 65:829-832.
63. Tarbardel Y, Paquay T, Senterre J: Prolonged infusion of atracurium in an infant. Dev Pharmacol Ther 1990, 15:52-56.